Silence Therapeutics Plc Stock Performance
| SLNCF Stock | USD 2.00 0.25 11.11% |
On a scale of 0 to 100, Silence Therapeutics holds a performance score of 9. The entity has a beta of 0.56, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Silence Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Silence Therapeutics is expected to be smaller as well. Please check Silence Therapeutics' kurtosis, and the relationship between the maximum drawdown and day median price , to make a quick decision on whether Silence Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Silence Therapeutics plc are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, Silence Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 20.6 M | |
| Total Cashflows From Investing Activities | 8.7 M |
Silence |
Silence Therapeutics Relative Risk vs. Return Landscape
If you would invest 145.00 in Silence Therapeutics plc on September 29, 2025 and sell it today you would earn a total of 55.00 from holding Silence Therapeutics plc or generate 37.93% return on investment over 90 days. Silence Therapeutics plc is currently producing 0.6587% returns and takes up 5.6735% volatility of returns over 90 trading days. Put another way, 50% of traded pink sheets are less volatile than Silence, and 87% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Silence Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Silence Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Silence Therapeutics plc, and traders can use it to determine the average amount a Silence Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1161
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SLNCF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Silence Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Silence Therapeutics by adding it to a well-diversified portfolio.
Silence Therapeutics Fundamentals Growth
Silence Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Silence Therapeutics, and Silence Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Silence Pink Sheet performance.
| Return On Equity | -1.43 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (2.24) % | |||
| Operating Margin | (2.99) % | |||
| Current Valuation | 240.14 M | |||
| Shares Outstanding | 107.68 M | |||
| Price To Earning | (17.50) X | |||
| Price To Book | 8.36 X | |||
| Price To Sales | 21.67 X | |||
| Revenue | 12.41 M | |||
| EBITDA | (45.42 M) | |||
| Cash And Equivalents | 51.56 M | |||
| Cash Per Share | 0.57 X | |||
| Total Debt | 52 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.95 X | |||
| Cash Flow From Operations | 6.81 M | |||
| Earnings Per Share | (0.53) X | |||
| Total Asset | 96.19 M | |||
About Silence Therapeutics Performance
By analyzing Silence Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Silence Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Silence Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Silence Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid therapeutics in hematology, cardiovascular, and other rare and metabolic indications. Silence Therapeutics plc is headquartered in London, the United Kingdom. Silence Therapeutics is traded on OTC Exchange in the United States.Things to note about Silence Therapeutics plc performance evaluation
Checking the ongoing alerts about Silence Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Silence Therapeutics plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Silence Therapeutics is way too risky over 90 days horizon | |
| Silence Therapeutics appears to be risky and price may revert if volatility continues | |
| Silence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.41 M. Net Loss for the year was (39.41 M) with profit before overhead, payroll, taxes, and interest of 4.96 M. | |
| About 57.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Silence Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Silence Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Silence Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Silence Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Silence Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Silence Therapeutics' pink sheet. These opinions can provide insight into Silence Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Silence Pink Sheet analysis
When running Silence Therapeutics' price analysis, check to measure Silence Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silence Therapeutics is operating at the current time. Most of Silence Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silence Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silence Therapeutics' price. Additionally, you may evaluate how the addition of Silence Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |